Detected ·
Kynexis
€40M—
Kynexis raised a €40M Series A extension (bringing total Series A to €97M), led by Novartis Venture Fund, to fund clinical development of KYN-5356, a potential first-in-class KAT-II inhibitor for cognitive impairment associated with schizophrenia.
- Website
- www.kynexistx.com
- linkedin.com/company/kynexis
- Amount
- €40 000 000 EUR
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-20 04:07:20 UTC
- Signal ID
- 780160e1-b997-454d-9e6e-33efe0a4811d
As the API returns it
{
"id": "780160e1-b997-454d-9e6e-33efe0a4811d",
"created_at": "2026-08-20T04:07:20.866611Z",
"company_name": "Kynexis",
"company_website_url": "www.kynexistx.com",
"company_linkedin_url": "https://www.linkedin.com/company/kynexis",
"event_type": "funding",
"funding_amount": 40000000,
"funding_currency": "EUR",
"funding_stage": null,
"message": "*Kynexis raised a €40M Series A extension (bringing total Series A to €97M), led by Novartis Venture Fund, to fund clinical development of KYN-5356, a potential first-in-class KAT-II inhibitor for cognitive impairment associated with schizophrenia.*"
}